The importance of insulin-like growth factor binding proteins (IGFBPs) 
The recent availability of recombinant DNA-derived insulin-like growth factor-f (fGF-I) for use in human trials has raised the possibility of a variety of therapeutic applications; for example as a growth stimulant in GHinsensitivity syndrome (Laron dwarflsm) and an insulin substitute in insulin-resistant subjects with type if diabetes mellitus. Endogenous serum IGFs circulate predominantly in a GH-dependent ternary complex with IGF binding protein-3 (IGFBP-3) and a non-IGF-binding glycoprotein, the acid-labile subunit or a-subunit (1, 2).
Studies in rats suggest that IGFBP-3 levels are inducible by IGF-I, whereas the a-subunit is GH-dependent (3). In the complexed form, IGFs are greatly stabilized (4) , and probably biologically inactive. Several other circulating IGFBPs are also thought to contribute to serum binding of ÍGFs; these include fGFBP-1, IGFBP-2 and IGFBP-4. IGFBP-1, which binds IGF-I and IGF-II with similar affinity (5) , differs from other well-characterized IGFBPs in that its serum concentration is regulated dynamically under the influence of insulin and metabolic status (6) (7) (8) (9) .
Since circulating IGFBPs have the potential to influence the biopotency of administered IGF-I, it is important to determine the IGFBP responses to IGF injection and infusion, in this study we examine the responses of ÎGFBP-1 and the IGFBP-3 complex to a single subcutaneous injection of IGF-I in fasted subjects, and to daily IGF-I injections for 7 days in fed subjects.
Materials and methods

Recombinant human IGF-I
Recombinant human ÍGF-I for administration was kindly provided by Fujisawa Pharmaceutical Co. Ltd., Osaka, Japan. It was dissolved in physiological saline at a concentration of 6 g/1 just before use.
Experimental procedures
All subjects entering the study had (10) . Blood glucose was measured by autoanalyzer. Serum levels of IGFBP-1, IGFBP-3 and asubunit were measured using previously described RIA methods (5, 12, 13) . Serum insulin was measured by commercially available RIA kit with a detection limit of 2.5 mU/1, and urinary GH was measured as previously reported (14) .
Ligand blotting
Five microliter aliquots of serum were fractionated, nonreduced, on 12% SDS-polyacrylamide gels overnight at 100 V, then proteins were transferred to Hybond-C Extra nitrocellulose membrane (Amersham, Bucks, UK) as previously described (15 next two days (Fig. 3a) . In contrast to the rapid increase in IGFBP-1 values after IGF-I administration, showed only a slight change (Fig. 3b) . After an apparent initial rise (not significant), IGFBP-3 levels declined between 6 and 36 h, with the 36-h value slightly lower than those determined from 0 to 10 h (p<0.05).
In the second study, IGF-I was administered to fed subjects daily for seven days, and blood samples were drawn over 24-h periods following the first and seventh injections. Free IGF-I levels from this study have pre¬ viously been reported (10) . There was a significant difference between the pattern of free IGF-I on days 1 (Fig. 4a) . in the subjects receiving fGF-I, however, a small increase in IGFBP-1, to a mean value (±se) of 48.6 ± 15.4 fig/l, was seen between 4 and 6 h after the day 1 injection (Fig. 4b) (Fig. 1) . This blunted response in fed subjects is consistent with the previously reported suppressive effect of food intake on IGFBP-1 levels (9 IGFBP-3 responses were also studied in these subjects. Analysis of all IGFBP-3 data indicated that daily IGF-I injections for seven days had a significant effect on IGFBP-3 levels compared to saline injections (treat-16 24 32
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Time (h) Fig. 3 . Changes in (a) serum IGF-I levels and (b) serum IGFBP-3 levels in the eight subjects described in Fig. 1 As seen for IGFBP-3 levels, treatment for seven days with ÎGF-I caused a significant decline in a-subunit levels (Fig. 6b) . integrated 24- 
Discussion
The hepatic production of fGFBP-1 is thought to be regulated by a cyclic nucleotide-dependent mechanism which can be activated by depriving the liver of meta¬ bolic substrate, and is potently inhibited by insulin (17, 18) . Consistent with the concept of stimulation by substrate deprivation, insulin-induced hypoglycemia (9) , fasting (9) and prolonged vigorous exercise (19) all greatly increase serum IGFBP-1 levels. However, since insulin, a potent suppressor of ÍGFBP-1 in vivo (6, 8) , falls under these conditions, the stimulatory effect of limited metabolic substrate is presumably comple¬ mented by a decrease in the inhibitory effect of insulin.
In this study we have shown that a single sc injection of human IGF-I in fasting subjects causes a rapid rise in IGFBP-levels, with little effect on IGFBP-3. Although IGF-I caused blood glucose levels to fall, as demonstrated previously in fasted humans (20) , hypoglycemia does not appear to be the major stimulus to IGFBP-1 secretion in these subjects, since the decline in glucose levels was minimal. Falling insulin levels after IGF-I administration may be an important stimulus to IGFBP-1 production. However, for the four fasting patients for whom insulin levels were measured, no significant association between insulin levels and the 6-h ÍGFBP-1 peak was seen at any time between 1 
